In the top 10 global drug sales in 2018,there are 8 antibody drugs, including 6 monoclonal antibody drugs, and thetotal sales of 2 fusion proteins account for 76% of the top 10 total sales. Sixof the eight anti-tumor drugs in the top 10 list are anti-tumor drugs (exceptadalimumab and arbacip), which are mainly aimed at the hot targets such as TNF- α, PD-1, HER-2, CD20 and VEGF. The anti-tumor drugs play an increasinglyimportant role in the field of tumor treatment.           

At present, China has become the countrywith the largest number of antibody drugs under research. More than 200antibody drugs have been approved for clinical trials. Some products havecompleted phase III clinical trials and submitted applications for marketregistration. At present, the most popular target of antibody drug research hasbeen approved for listing in 9 varieties, and the products of many enterprisesare in the stage of market approval or phase III clinical stage.           

Alit Life Science Co., Ltd. has been engagedin the antibody industry for many years. It has independently developedcountstar series cell analyzers, integrated the advanced biopharmaceuticaltechnology in Europe and the United States, and the whole process of asepticcontrol solutions. It provides the international advanced high-quality and highstability compliance instruments and technical services for the upstream anddownstream process of the antibody industry and the filling process ofpreparations, so as to reduce Operating costs and risks to improve thecompetitiveness of the industry.